Search
Ibutilide
go.drugbank.com/drugs/DB00308ApprovedIbutilide is a Class III antiarrhythmic agent available in intravenous formulations.
Seletracetam
go.drugbank.com/drugs/DB05885InvestigationalSeletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. … As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLactobacillus plantarum
go.drugbank.com/drugs/DB11360Investigational*Lactobacillus plantarum* is a member of Lactobacillus, or lactic acid bacteria, that it is widely used in the food industry as a microbial starter and probiotic microorganism. … *L. plantarum* produces different antimicrobial agents such as organic acids, hydrogen peroxide, diacetyl, bacteriocins, and antimicrobial peptides [A27208].
Ormeloxifene
go.drugbank.com/drugs/DB13310ExperimentalIn India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week,[A251450] and it was later introduced for the treatment of dysfunctional uterine … [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) and d-isomers (d-ormeloxifene) of _trans_-ormeloxifene.
R343
go.drugbank.com/drugs/DB06316InvestigationalR343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB15845ExperimentalAs of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ … The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.
Synonyms: AP-TP-V, COVID-19 AP TP VaccineRO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.
FB-825
go.drugbank.com/drugs/DB17598InvestigationalFB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. … It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]
CTx-PDE6b
go.drugbank.com/drugs/DB17858InvestigationalCTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.
KAI-1455
go.drugbank.com/drugs/DB06064ExperimentalKAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.